Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dolors Carrion-Salip

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Molecular Pharmaceutics|March 21, 2013
Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cellsAriadna Grau-Campistany, Anna Massaguer, Dolors Carrion-Salip, et al.
Bioconjugate Chemistry|August 9, 2012
Somatostatin subtype-2 receptor-targeted metal-based anticancer complexesFlavia Barragán, Dolors Carrion-Salip, Irene Gómez-Pinto, et al.
Investigational New Drugs|December 17, 2010
Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cellsCristina Oliveras-Ferraros, Anna Massaguer Vall-Llovera, Dolors Carrion Salip, et al.
Oncology Reports|March 20, 2012
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatmentCristina Oliveras-Ferraros, Anna Massaguer Vall-Llovera, Alejandro Vazquez-Martin, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Molecular Pharmaceutics|March 21, 2013
Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cellsAriadna Grau-Campistany, Anna Massaguer, Dolors Carrion-Salip, et al.
Bioconjugate Chemistry|August 9, 2012
Somatostatin subtype-2 receptor-targeted metal-based anticancer complexesFlavia Barragán, Dolors Carrion-Salip, Irene Gómez-Pinto, et al.
Investigational New Drugs|December 17, 2010
Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cellsCristina Oliveras-Ferraros, Anna Massaguer Vall-Llovera, Dolors Carrion Salip, et al.
Oncology Reports|March 20, 2012
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatmentCristina Oliveras-Ferraros, Anna Massaguer Vall-Llovera, Alejandro Vazquez-Martin, et al.
Pageof 1